Today: 28 June 2026
Browse Category

Biotechnology 4 May 2026 - 20 May 2026

Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

Immunovant shares jumped 35.3% to $35.56 after reporting 16-week data showing its drug IMVT-1402 produced ACR20, ACR50, and ACR70 response rates of 72.7%, 54.5%, and 35.8% in difficult-to-treat rheumatoid arthritis. Roivant Sciences, its majority owner, rose 14.9%. No new safety signals were reported. The trial enrolled 170 patients, most of whom had failed two prior advanced therapies.
20 May 2026
···
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
20 May 2026
·
Silexion’s Cancer Trial Push Puts Focus on Cash

Silexion’s Cancer Trial Push Puts Focus on Cash

Silexion reported Israeli clearance and a German filing for its SIL204 pancreatic cancer drug, keeping its Phase 2/3 trial on track for a second-quarter start. The company posted a first-quarter net loss of $2.7 million and held $2.4 million in cash at March 31. Shares closed at 26.9 cents Tuesday after a sharp drop last week. Management warned of “substantial doubt” about ongoing operations without new funding.
20 May 2026
··
Co-Diagnostics Jumps; $3 Million Deal Looms

Co-Diagnostics Jumps; $3 Million Deal Looms

Co-Diagnostics announced a $3 million private placement after its stock surged 43.8% Tuesday, then fell 13.3% in after-hours trading. The company will sell 1.65 million shares or pre-funded warrants, plus warrants for up to 3.29 million more shares, nearly doubling its share count. The move follows its completion of a Bundibugyo virus assay as Ebola spreads in Congo and Uganda. Co-Diagnostics reported $8.2 million in cash at March 31.
20 May 2026
··
Co-Diagnostics Stock Surges on Ebola Assay News — The Fine Print Is Big

Co-Diagnostics Stock Surges on Ebola Assay News — The Fine Print Is Big

Co-Diagnostics shares surged 51% Tuesday after the company announced completion of an assay strategy for the Bundibugyo Ebola virus, though the test is not yet for sale and awaits regulatory approval. Trading volume topped 94 million shares. The company reported $8.23 million in cash at March 31 and a quarterly net loss of $9.14 million, raising concerns about its financial stability.
19 May 2026
···
Tonix Pharma Stock Gains After Antibody News, 2027 Lyme Trial Planned

Tonix Pharma Stock Gains After Antibody News, 2027 Lyme Trial Planned

Tonix Pharmaceuticals filed new Phase 1 modeling data showing its experimental Lyme disease antibody, TNX-4800, could maintain serum levels above a proposed protective threshold for six months with a two-dose regimen. Shares rose $1.65 to $15.74 Friday. The company plans a Phase 2 trial in 2027, pending FDA agreement. No Lyme vaccine is currently available in the U.S.
15 May 2026
···
REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions

REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions

REGENXBIO shares fell 37% to $6.31 after its Duchenne muscular dystrophy gene therapy, RGX-202, met the main goal in a late-stage trial. Investors reacted to two serious adverse events and uncertainty over FDA approval. The company reported 93% of patients showed microdystrophin expression at 12 weeks. REGENXBIO said it will seek accelerated approval and targets a 2027 launch.
14 May 2026
····
WORK Medical Technology Group Stock Triples After AI BioToken Deal — What Investors Need to Know

WORK Medical Technology Group Stock Triples After AI BioToken Deal — What Investors Need to Know

WORK Medical Technology Group’s Nasdaq-listed shares surged 206% Monday to $3.92 after announcing an AI partnership with Shanghai Novabioplus Biotechnology. The stock swung between $0.19 and $4.09 before falling 48% in early Tuesday premarket. The companies plan to develop AI-driven models for protein and biological data but disclosed no financial terms or customer details.
12 May 2026
···
Moderna Stock Gets Fresh Hantavirus Jolt As Cruise-Ship Outbreak Widens

Moderna Stock Gets Fresh Hantavirus Jolt As Cruise-Ship Outbreak Widens

Moderna’s early-stage hantavirus vaccine research drew renewed attention after a deadly Andes virus outbreak on the MV Hondius cruise ship, with six confirmed cases and three deaths reported. Moderna shares closed up nearly 12% Friday. WHO and ECDC rated the broader public risk as low, but recommended a 42-day quarantine for passengers. No approved vaccine or treatment for Andes virus exists, according to the CDC.
11 May 2026
··
Moderna Stock Surges on Hantavirus Vaccine Research as MRNA Investors Eye Flu and Cancer Pipeline

Moderna Stock Surges on Hantavirus Vaccine Research as MRNA Investors Eye Flu and Cancer Pipeline

Moderna confirmed early-stage research on hantavirus vaccines with U.S. Army and Korea University partners, following a deadly outbreak on the MV Hondius cruise ship. Eight cases, including three deaths, have been reported; six cases are confirmed. Moderna shares rose 11.9% to $54.35. Spain and several EU countries are preparing evacuations as the ship nears Tenerife.
9 May 2026
··
Moderna Stock Surges on Hantavirus Vaccine News as Cruise Outbreak Puts mRNA Pipeline Back in Focus

Moderna Stock Surges on Hantavirus Vaccine News as Cruise Outbreak Puts mRNA Pipeline Back in Focus

Moderna shares rose about 10% Friday after the company announced research into vaccines for hantaviruses amid a deadly Andes virus outbreak linked to the MV Hondius cruise ship. WHO reported eight cases and three deaths, with five confirmed as hantavirus. Moderna’s vaccine program is in early stages, with commercial availability still years away. The U.S. is arranging a repatriation flight for 17 Americans from the ship.
8 May 2026
·
Bayer’s $2.45 Billion Perfuse Deal Puts Eye-Drug Pipeline Back in Focus

Bayer’s $2.45 Billion Perfuse Deal Puts Eye-Drug Pipeline Back in Focus

Bayer agreed to acquire Perfuse Therapeutics for up to $2.45 billion, including $300 million upfront, to gain access to a mid-stage eye-disease drug, PER-001. Eylea, Bayer’s top-selling eye drug, saw 2025 sales fall 5.9% to €3.11 billion amid generic competition. The deal awaits antitrust and shareholder approval. PER-001 is in Phase II trials for glaucoma and diabetic retinopathy.
6 May 2026
··
Why Ernexa Therapeutics Stock Jumped After ERNA-101 Ovarian Cancer Survival Data

Why Ernexa Therapeutics Stock Jumped After ERNA-101 Ovarian Cancer Survival Data

Ernexa Therapeutics said its ERNA-101 cell therapy plus PD-1 blockade cleared tumors and achieved 100% long-term survival in preclinical ovarian cancer models. Shares jumped about 60% after the announcement, trading between $3.70 and $7.66. The company remains preclinical and recently completed a 1-for-25 reverse stock split to maintain its Nasdaq listing.
6 May 2026
···
Avalo Therapeutics Stock Jumps As $375 Million Raise Follows Phase 2 HS Trial Win

Avalo Therapeutics Stock Jumps As $375 Million Raise Follows Phase 2 HS Trial Win

Avalo Therapeutics priced a $375 million public offering after reporting positive Phase 2 results for abdakibart in hidradenitis suppurativa. The company will sell 19.73 million shares at $17.75 each and pre-funded warrants for 1.4 million shares. Shares rose 34% to $21.73 by midday. The Phase 2 trial showed HiSCR75 response rates of over 42% for both dosing regimens versus 25.6% for placebo.
6 May 2026
··
GeneDx Stock Crash: WGS Plunges After Guidance Cut Raises Reimbursement Fears

GeneDx Stock Crash: WGS Plunges After Guidance Cut Raises Reimbursement Fears

GeneDx shares dropped 51% to $33.12 after the company cut its 2026 revenue forecast and lowered full-year guidance to $475–$490 million. First-quarter revenue rose 17% to $102.3 million, but missed expectations as reimbursement rates and product mix hurt sales. The company posted an adjusted net loss of $8.2 million. Management maintained its target for positive adjusted net income this year.
5 May 2026
····
Lunai Bioworks Stock: $20 Million Patent Deal Puts Nasdaq Fight in Focus

Lunai Bioworks Stock: $20 Million Patent Deal Puts Nasdaq Fight in Focus

Lunai Bioworks issued $20 million in Series B preferred stock to acquire Neurobridge IP Holdings’ CNS drug-delivery and neurotherapeutic patents, closing the deal May 1. The company said the transaction lifts its stockholders’ equity above Nasdaq’s $2.5 million listing minimum. Lunai shares traded at $0.3246 Monday, leaving its market value at $7.6 million. The acquired assets consist solely of patents, with no cash paid.
4 May 2026
···
1 2 3 4 … 19

Stock Market Today

  • Dodla Dairy Earnings Highlight Profit Boost from Unusual Items
    June 28, 2026, 12:01 AM EDT. Dodla Dairy Limited's latest earnings reveal a ₹246 million boost from unusual items, raising concerns about the sustainability of profit growth. Despite strong earnings per share growth over three years, the one-off nature of these gains suggests potential profit declines if such contributions do not recur. Analysts emphasize caution interpreting statutory profits as a true reflection of ongoing business performance. Investors should consider underlying risks flagged by market data and examine broader financial metrics such as return on equity and insider holdings. The mixed signals have kept the stock price largely unchanged, indicating market apprehension about earnings quality and future profitability.

Latest articles

Hecla Mining (NYSE:HL) sees stock rebound, volume jumps as silver prices in focus

Hecla Mining (NYSE:HL) sees stock rebound, volume jumps as silver prices in focus

28 June 2026
Hecla Mining surged 5.3 times its average trading volume Friday as index rebalancing drove 112.44 million shares traded, but the stock’s 2.6% weekly drop still beat silver and peer ETFs, signaling company-specific strength; investors now watch if Hecla can hold above $15.54 without rebalancing flows as macro risks loom.
Go toTop